Estrogen receptor-mediated neuroprotection: The role of the Alzheimer's disease-related gene seladin-1

Neuropsychiatric Disease and Treatment

Volumn 4, Issue 4, 2008, Pages 817-824

  Peri, Alessandro ^a   Serio, Mario ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Alzheimer's disease; Brain; DHCR24; Estrogen; Seladin 1

Indexed keywords

1,3,5 TRIS(4 HYDROXYPHENYL) 4 PROPYLPYRAZOLE; 3BETA HYDROXY DELTA5 STEROID DEHYDROGENASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; BETA SECRETASE; BRAIN PROTEIN; CASPASE 3; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; RALOXIFENE; SELADIN 1; SELECTIVE ALZHEIMER DISEASE INDICATOR 1 PROTEIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; APOPTOSIS; CLINICAL TRIAL; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG PENETRATION; ENZYME ACTIVITY; ESTROGEN THERAPY; GENE CONTROL; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE ISOLATION; HORMONE SUBSTITUTION; HUMAN; HYPOTHESIS; MENOPAUSAL SYNDROME; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIMARY PREVENTION; PROTEIN FUNCTION; REVIEW; RISK FACTOR; RISK REDUCTION; UPREGULATION;

EID: 52649175477     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/ndt.s3637     Document Type: Review

References (40)

1. Abad-Rodriguez J, Ledesma MD, Craessaerts K, et al. 2004. Neuronal membrane cholesterol loss enhance amyloid peptide generation. J Cell Biol, 167:953-60.
2. Arbogast LA. 2008: Estrogen genomic and membrane actions at an intersection. Trends Endocrinol Metab, 19:1-2.
3. Arispe N, Doh M. 2002. Plasma membrane cholesterol controls the cytotoxicity of Alzheimer's disease AbetaP (1-40) and (1-42) peptides. FASEB J, 16:1526-36.
4. Barni T, Maggi M, Fantoni G, et al. 1999. Sex steroids and odorants modulate gonadotropin-releasing hormone secretion in primary cultures of human olfactory cells. J Clin Endocrinol Metab, 84:4266-73.
5. Behl C. 2003. Estrogen can protect neurons: modes of action. J Steroid Biochem Mol Biol, 83:195-197.
6. Benvenuti S, Luciani P, Vannelli GB, et al. 2005. Estrogen and SERMs exert neuroprotective effects and stimulate the expression of seladin-1, a recently discovered anti-apoptotic gene, in human neuroblast long-term cell cultures. J Clin Endocrinol Metab, 90:1775-82.
7. Dhandapani KM, Brann DW 2002. Protective effects ofestrogen and selective estrogen receptor modulators in the brain. Biol Reprod, 67:1379-85.
8. Dubai DB, Zhu H, Yu J, et al. 2001. Estrogen receptor alpha, not beta, is a critical link in esradiol-mediated protection against brain injuery. Proc Natl Acad Sci USA, 98:1952-57.
9. Fillit HM. 2002. The role of hormone replacement therapy in the prevention ofAlzheimer's disease. Arch Intern Med, 162:1934-42.
10. Fitzpatrick DR, Keeling JW, Evans MJ, et al. 1998. Clinical phenotype of desmosterolosis. Am JMed Genet, 75:145-52.
11. Greeve I, Hermans-Borgmeyer I, Brellinger C, et al. 2001. The human DIMINUTO/DWARF1 homolog seladin-1 confers resistance to Alzheimer's disease-associated neurodegeneration and oxidative stress. J Neurosci, 20:7345-52.
12. Harrington WR, Sheng S, Barnett DH et al. 2003. Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression. Mol Cell Endocrinol, 206:13-22.
13. Hawkins MB, Thornton JW, Crews D, et al. 2000. Identification of a third distinct estrogen receptor and reclassification of estrogen receptors in teleosts. Proc Natl Acad Sci USA, 97:10751-6.
14. Herman GE. 2003. Disorders of cholesterol biosynthesis: prototypic metabolic malformation syndromes. Hum Mol Genet, 12 Spec No 1:R75-88.
15. Hu XY, Qin S, Lu YP, et al. 2003. Decreased estrogen receptor-α expression in hippocampal neurons in relation to hyperphosphorylated tau in Alzheimer patients. Acta Neuropathol, 106:213-20.
16. Iivonen S, Hiltunen M, Alafuzoff I, et al. 2002. Seladin-1 transcription is linked to neuronal degeneration in Alzheimer's disease. Neuroscience, 113:301-10.
17. MacLusky NJ. 2004. Estrogen and Alzheimer's disease: the apolipoprotein connection. Endocrinology, 145:3062-4.
18. Maggi A, Ciana P, Belcreditc, S, et al. 2004. Estrogens in the nervous system:mechanisms and nonreproductive functions. Ann Rev Physiol, 66:291-313.
19. Mirza R, Hayasaka S, Takagishi Y, et al. 2006. DHCR24 gene knockout mice demonstrate lethal dermopathy with differentiation and maturation defects in the epidermis. J Invest Dermatol, 126:638-47.
20. Luciani P, Deledda C, Rosati F, et al. 2008. Seladin-1 is a fundamental mediator of the neuroprotective effects of estrogen in human neuroblast long-term cell cultures. Endocrinology, [Equb ahead of print].
21. O'Neill K, Chen S, Brinton RD. 2004a. Impact of the selective estrogen receptor modulator, raloxifene, on neuronal survival and outgrowth following toxic insults associated with aging and Alzheimer's disease. Exp Neurol, 185:63-80.
22. O'Neill K, Chen S, Brinton RD. 2004b. Impact of the selective estrogen receptor modulator, tamoxifen, on neuronal outgrowth and survival following toxic insults associated with aging and Alzheimer's disease. Exp Neurol, 188:268-78.
23. Paganini-Hill A, Henderson VW. 1994. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemol, 140:256-61.
24. Puglielli L, Tanzi RE, Kovacs DM. 2003. Alzheimer's disease: the cholesterol connection. Nat Neurosci, 6:345-51.
25. Rapp SR, Espeland MA, Shumaker SA, et al. 2003. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA, 289:2663-72.
26. Reiss AB, Siller KA, Rahman MM, et al. 2004. Cholesterol in neurologic disorders of the elderly: stroke and Alzheimer's disease. Neurobiol Aging, 25:977-89.
27. Resnick SM, Henderson VW. 2002. Hormone therapy and risk of Alzheimer disease. JAMA, 288:2170-2.
28. Schumacher M, Guennoun R, Ghoumaru A, et al. 2007. Novel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system. End Rev, 28:387-439.
29. Selkoe DJ. 2001. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev, 81:741-76.
30. Shumaker SA, Legault C, Rapp SR, et al. 2003. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in post-menopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA, 289:2651-62.
31. Toran-Allerand CD. 2004. Minireview: a plethora of estrogen receptors in the brain:where will it end? Endocrinology, 145:1069-74.
32. Turgeon JL, Carr MC, Maki PM, et al. 2006. Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: insights from basic science and clinical studies. End Rev, 27:576-605.
33. Vannelli GB, Ensoli F, Zonefrati R, et al. 1995. Neuroblast long-term cell cultures from human fetal olfactory epithelium respond to odors. J Neurosci, 15:4282-94.
34. Wang L, Andersson S, Warner M, et al. 2001. Morphological abnormalities in the brains of estrogen receptor beta knockout mice. Proc Natl Acad Sci USA, 98:2792-6.
35. Waterham HR, Koster J, Romeijn GJ, et al. 2001. Mutations in the 3beta-hydroxysterol Delta24-reductase gene cause desmosterolosis, an autosomal recessive disorder of cholesterol biosynthesis. Am J Hum Genet, 69:685-94.
36. Wechsler A, Brafman A, Shafir M, et al. 2003. Generation of viable cholesterol-free mice. Science, 302:2087.
37. Wu C, Miloslavskaya I, Demontis S, et al. 2004. Regulation of cellular response to oncogenic and oxidative stress by Seladin-1. Nature, 432:640-5.
38. Yaffe K, Krueger K, Cummings SR, et al. 2005. Effect of raloxifene on prevention of dementia and cognitive imparirment in older women: the Multiple Outcome of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry, 162:683-90.
39. Yanagisawa K. 2002. Cholesterol and pathological processes in Alzheimer's disease. J Neurosci Res, 70:361-6.
40. Zandi PP, Carlson MC, Plassman BL, et al. 2002. Hormone replacement therapy and incidence of Alzheimer disease in older women. JAMA, 288:2123-9.